Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 82300446 | Other Grant/Funding Number | National Science Foundation of China | |
| 2022A1515111093 | Other Grant/Funding Number | Guangdong Basic and Applied Basic Research Foundation | |
| RCBS20231211090745071 | Other Grant/Funding Number | Shenzhen Science and Technology Program |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.
The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Measurement of serum miR-455-5p level | concentration of microRNA-455-5p in 100ml serum was determined by Elisa assay. | the miR-455-5p level is collected at week 0, 6, 12 and 24. |
| Measurement of LVPWd and LVPWs | left ventricular posterior wall thickness in diastole state and systole state are measured and recorded by echocardiography and its affiliated software. | the LVPWd and LVPWs are collected at week 0, 6, 12 and 24. |
| Measurement of LVIDd and LVIDs | left ventricular internal diameter in diastole state and systole state are measured and recorded by echocardiography and its affiliated software. | the LVIDd and LVIDs are collected at week 0, 6, 12 and 24. |
| Measurement of IVSTd and IVSTs | interventricular septum in diastole state and systole state are measured and recorded by echocardiography and its affiliated software. | the IVSTd and IVSTs are collected at week 0, 6, 12 and 24. |
| Calculation of LVMi | left ventricular mass index was calculated based on the formula: LVMi=LVM/BSA; For LVM, LVM(g)=0.8*1.04*[(IVSTd+LVPWd+LVIDd)^3-LVIDd^3]+0.6; For BSA, BSA=[Body height (cm)*Body weight (kg)/3600]^0.5ï¼› Diagnosis of LVH: LVMi(Male)>115g/m2ï¼›LVMi(Female)>95g/m2 | the LVMi is calculated at week 0, 6, 12 and 24. |
| Measurement of LVEF | left ventricular ejection fraction are measured and recorded by echocardiography and its affiliated software. Generally, LVEF is range from 50% to 70% is regarded as normal. If LVEF less than 50%, the patient is suspected to suffered cardiac systolic dysfunction. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
45 patients with hypertensive heart disease admitted to Hong-Kong University, Shenzhen Hospital from January 1 to March 10 in 2021 were included in our study. Hypertensive heart disease was defined using the International Classification of Diseases, Ninth and Tenth Revision (ICD-10) codes. Diseases coded as I11.0 and I11.9 in ICD-10 were identified as hypertensive heart disease[1-2].
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Assistant research fellow | The University of Hong Kong-Shenzhen Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| the University of Hongkong-Shenzhen Hospital | Shenzhen | Guangdong | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D006331 | Heart Diseases |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
serum
| the EF is calculated at week 0, 6, 12 and 24. |
| Measurement of FS | Fractional shortening are measured and recorded by echocardiography and its affiliated software. Generally, FS is range from 25% to 45% is regarded as normal. If FS less than 25%, the patient is suspected to suffered cardiac systolic dysfunction. | the FS is calculated at week 0, 6, 12 and 24. |
| SBP | systolic blood pressure was measured by sphygmomanometer. For patients whose SBP is higher than 140mmHg, the patients is regarded as hypertension. | the SBP is collected at week 0, 6, 12 and 24. |
| DBP | diastolic blood pressure was measured by sphygmomanometer. For patients whose DBP is higher than 90mmHg, the patients is regarded as hypertension. | the DBP is collected at week 0, 6, 12 and 24. |